Ramucirumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma
Trial Timeline
Jul 20, 2015 → Nov 19, 2021
NCT ID
NCT02435433About Ramucirumab + Placebo
Ramucirumab + Placebo is a phase 3 stage product being developed by Eli Lilly for Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02435433. Target conditions include Hepatocellular Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02435433 | Phase 3 | Completed |
| NCT00917384 | Phase 3 | Completed |
Competing Products
20 competing products in Hepatocellular Carcinoma